FindTrial
Sign In

Parasetamolin käyttö oheiskipulääkkeenä oksikodonin kanssa ohitusleikkauksen jälkeisen kivun hoidossa Paracetamol as Adjuctive Treatment for Postoperative Pain after Off-Pump Bypass Surgery - PARA-CABG-01

Parasetamolin käyttö oheiskipulääkkeenä oksikodonin kanssa ohitusleikkauksen jälkeisen kivun hoidossa Paracetamol as Adjuctive Treatment for Postoperative Pain after Off-Pump Bypass Surgery - PARA-CABG-01

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-008235-28-FI
Enrollment
60
Registered
2008-12-10
Start date
2009-01-28
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with chronic ischemic heart disease ongoing elective coronary artery bypass grafting. Any major organ failures like heart, kidney, liver failures are excluded. MedDRA version: 9.1 Level: LLT Classification code 10008937 Term: Chronic ischemic heart disease, unspecified

Interventions

Trade Name: Perfalgan Pharmaceutical Form: INN or Proposed INN: PARACETAMOL CAS Number: 103902 Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intrave

Sponsors

Vesa Pakanen
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026